



Peptide-Based Drug Development

Guest Editors:

Prof. Dr. William D. Lubell

Department of Chemistry,
Université de Montréal, Montréal,
QC H2V 0B3, Canada

Prof. Jackie Wilce

Department of Biochemistry and
Molecular Biology, School of
Biomedical Sciences, Monash
University, Melbourne, Australia

Dr. Johan Rosengren

School of Biomedical Sciences,
Faculty of Medicine, University of
Queensland, Brisbane, Australia

Deadline for manuscript
submissions:

closed (31 May 2022)

Message from the Guest Editors

Dear Colleagues,

Peptides and their analogs are readily accessible by chemical and biological methods. With ideal properties for forming high affinity and specific interactions with target protein surfaces, they have established an important niche in the drug development spectrum complementing small molecule and biological therapeutics. Among the most successful biomedicines in use today, peptide-based drugs show great promise for the future. The theme issue “Peptide-Based Drug Development” invites contributions across the spectrum of advances, including novel bioactive peptides, library-based peptide lead discovery, and chemistry for improving peptide pharmacokinetic (ADMET) properties.

Prof. Dr. William D. Lubell
Assoc. Prof. Jackie Wilce
Dr. Johan Rosengren
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)